Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo RecondoMagda BahcallLiam F SpurrJianwei CheBiagio RicciutiGiulia C LeonardiYing-Chun LoYvonne Y LiGiuseppe LambertiTom NguyenMarina S D MilanDeepti VenkatramanRenato UmetonCloud P PaweletzAdem AlbrayakAndrew D CherniackKristin S PriceStephen R FaircloughMizuki NishinoLynette M ShollGeoffrey R OxnardPasi A JänneMark M AwadPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
On-target secondary mutations and activation of bypass signaling drive resistance to MET TKIs. A deeper understanding of these molecular mechanisms can support the development of sequential or combinatorial therapeutic strategies to overcome resistance.